Immunosuppressive effect on T cell activation by interleukin- 16-cDNA-transfected human squamous cell line.
It is well known that it is difficult to induce an immunotolerance with allogeneic skin transplantation. We attempted to find the immunosuppressive protocol for prolonging skin allograft rejection by using interleukin-16 because IL-16 is considered one of the natural ligands to CD4 molecules. First we examined whether synergistic immunosuppressive effects of recombinant IL-16 plus anti-CD4 mAbs are induced in mixed lymphocyte reaction (MLR). Next we used IL-16-cDNA-transfected OSC-20 (human oral squamous cell carcinoma cell line) as an in vitro model of the epidermal keratinocyte equivalent and examined whether this transfectant could inhibit the activation of allogeneic T cells. Our data indicated that IL-16 clearly inhibited human MLR and that IL-16 increased synergistically the immunosuppressive effect of anti-CD4 mAb. We also used IL-16 transfectant and this produced more than 50 ng/ml of IL-16 in the supernatant by which human MLR was significantly inhibited. Furthermore, this transfectant also inhibited the activation of allogeneic lymphocytes stimulated directly with transfectant cells. These results indicated that the IL-16-producing allogeneic skin graft might have a local immunosuppressive action that would prolong graft survival.
Fujita
T
T
Division of Plastic Surgery, Sapporo Medical University School of Medicine, Sapporo, 060-8543, Japan. tfujita@sapmed.ac.jp
Matsumoto
Y
Y
Hirai
I
I
Ezoe
K
K
Saito
T
T
Yagihashi
A
A
Torigoe
T
T
Homma
K
K
Takahashi
S
S
Cruikshank
W W
WW
Jimbow
K
K
Sato
N
N
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D015704:CD4 Antigens / Q000276:immunology*; D002460:Cell Line; D018076:DNA, Complementary; D004357:Drug Synergism; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D019410:Interleukin-16 / Q000235:genetics / Q000494:pharmacology*; D015603:Keratinocytes / Q000276:immunology*; D008213:Lymphocyte Activation / Q000187:drug effects*; D007959:Lymphocyte Culture Test, Mixed; D011994:Recombinant Proteins / Q000494:pharmacology; D016038:Skin Transplantation / Q000276:immunology; D014162:Transfection; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D018076:DNA, Complementary; D007166:Immunosuppressive Agents; D019410:Interleukin-16; D011994:Recombinant Proteins